Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.

David I QuinnDenice D Tsao-WeiPrzemyslaw TwardowskiAna M AparicioPaul FrankelGurkamal ChattaJohn J WrightSusan G GroshenStella KhooHeinz-Josef LenzPrimo N LaraDavid R GandaraEdward Newman

Published in: Investigational new drugs (2021)

Vorinostat on this dose-schedule had limited efficacy and significant toxicity resulting in a unfavorable risk:benefit ratio in patients with mUC. NCT00363883.

Keyphrases

histone deacetylase
phase ii study
open label
papillary thyroid
locally advanced
phase iii
phase ii
squamous cell carcinoma
study protocol
small cell lung cancer
clinical trial
squamous cell
placebo controlled
oxidative stress
randomized controlled trial
rectal cancer
lymph node metastasis